Evolution Research Group | Endeavor Clinical Trials
Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent the worsening of kidney function. The trial will enroll adults with body mass index 27 kg/m^2 or higher and Atherosclerotic Cardiovascular Disease and/or chronic kidney disease. The study will last for about 5 years. Participants will have up to 27 clinic visits with the study doctor.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
A Body Mass Index of ≥27.0 kilograms per meter squared (kg/m^2)
Participants may be with or without type 2 diabetes (T2D) unless their hemoglobin A1c (HbA1c) is 10% or lower
Participants have established atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD), as evidenced at least one of the following:
Coronary artery disease
Cerebrovascular disease
Peripheral arterial disease
Chronic kidney disease defined as:
Exclusion criteria
Diabetes related:
CV related:
Participants have any of the following cardiovascular conditions ≤ 90 days prior to randomization:
Have acute decompensated heart failure requiring hospitalization.
Have New York Heart Association (NYHA) Classification Class IV heart failure at screening
Kidney related:
Other medical conditions:
Primary purpose
Allocation
Interventional model
Masking
10,000 participants in 2 patient groups, including a placebo group
Loading...
Central trial contact
There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal